HLUBF (H. Lundbeck AS) Investments And Advances : $0 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Investments And Advances?

H. Lundbeck AS's Investments And Advances for the quarter that ended in Dec. 2024 was $0 Mil.

H. Lundbeck AS Investments And Advances Historical Data

The historical data trend for H. Lundbeck AS's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Investments And Advances Chart

H. Lundbeck AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Investments And Advances

Get a 7-Day Free Trial

H. Lundbeck AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Investments And Advances	Get a 7-Day Free Trial															-	-	-	-	-

H. Lundbeck AS Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

H. Lundbeck AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OTCPK:HLUBF) » Definitions » Investments And Advances

Traded in Other Exchanges

HLBBF:USA 0ABR:UK 0ND5:UK HLUN A:Denmark HLUN B:Denmark LDBB:Germany LUNB:Austria LUNA:Austria

Address

Ottiliavej 9, Valby, DNK, 2500

Website

https://www.lundbeck.com

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.